Oppenheimer on TransMedics Group (TMDX): 'Concerns on Jet Fuel Costs Misplaced'

April 7, 2026 6:02 AM

Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $175.00 price target on TransMedics Group (NASDAQ: TMDX)The analyst comments "Rising ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found